Welwyn, United Kingdom

Tomasz Kostrzewski

This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Imperial College Innovations Limited. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Tomasz Kostrzewski

Introduction

Tomasz Kostrzewski is a notable inventor based in Welwyn, GB. He has made significant contributions to the field of biotechnology, particularly in the area of natural killer (NK) cells. His work focuses on enhancing the therapeutic applications of these cells, which play a crucial role in the immune response.

Latest Patents

Kostrzewski holds a patent related to Natural Killer (NK) cell populations. This invention pertains to methods of producing NK cells and their therapeutic applications. More specifically, it involves the expansion of NK cells by increasing the expression of specific transcription factors associated with NK cell production. He has 1 patent to his name, showcasing his innovative approach to biotechnology.

Career Highlights

Kostrzewski is associated with Imperial College Innovations Limited, where he continues to develop his research and inventions. His work is instrumental in advancing the understanding and application of NK cells in medical therapies.

Collaborations

He has collaborated with notable colleagues such as Hugh J M Brady and Matthew John Fuchter. These partnerships enhance the research and development efforts in the field of immunology.

Conclusion

Tomasz Kostrzewski's contributions to the field of biotechnology, particularly through his patent on NK cells, highlight his innovative spirit and dedication to advancing medical science. His work has the potential to impact therapeutic applications significantly.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…